CliffBio
small molecule

TRIUMEQ

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyViiV Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameTRIUMEQ
Active ingredientABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE
StrengthEQ 600MG BASE;EQ 50MG BASE;300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2014
Marketing statusRX

Listed patents

PatentExpiresType
9242986*PEDJune 2030—
9242986December 2029substance, product
8129385*PEDApril 2028—
8129385October 2027substance, product

Regulatory exclusivity

CodeExpires
PEDDecember 2026
M-294June 2026

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TRIUMEQ patent cliff — loss of exclusivity June 2030 | CliffBio